摘要
吸入制剂用于治疗肺部感染性疾病可将药物直接递送至靶向部位,以提高药效,降低药物剂量,并减轻全身不良反应。本文简要综述用于肺部感染性疾病的吸入制剂的临床应用及研发进展,为该类制剂的临床应用与开发研究提供参考。
Inhaled formulation can directly deliver the drug to the target site. For the treatment of pulmonary infections, it can improve the efficacy and reduce the dose and the systemic adverse reactions. This article briefly reviews the clinical applications and progress research of inhalation formulations applied in pulmonary infections, so as to provide references for the clinical application of this dosage forms.
作者
丁云娜
康彬
王健
DING Yun-na KANG Bin WANG Jian(National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201213 Department of Respiratory, Siting Hospital of Songjiang District, Shanghai 201601, China)
出处
《世界临床药物》
CAS
2016年第10期712-716,共5页
World Clinical Drug
基金
上海市研发公共服务平台能力提升专项(编号:2015DZ2290600)
关键词
吸入制剂
肺部感染性疾病
药物开发
inhalation formulatios
pulmonary infections
drug development
